U.S. Markets close in 4 hrs 30 mins
  • S&P 500

    4,478.67
    +7.30 (+0.16%)
     
  • Dow 30

    35,278.86
    -15.90 (-0.05%)
     
  • Nasdaq

    14,940.61
    +43.27 (+0.29%)
     
  • Russell 2000

    2,264.02
    -1.64 (-0.07%)
     
  • Gold

    1,769.00
    +0.70 (+0.04%)
     
  • EUR/USD

    1.1608
    +0.0007 (+0.0580%)
     
  • 10-Yr Bond

    1.5980
    +0.0790 (+5.20%)
     
  • Vix

    16.69
    +0.39 (+2.39%)
     
  • GBP/USD

    1.3716
    +0.0039 (+0.2867%)
     
  • USD/JPY

    114.2300
    +0.5530 (+0.4865%)
     
  • BTC-USD

    61,836.23
    +1,031.04 (+1.70%)
     
  • CMC Crypto 200

    1,440.84
    -10.79 (-0.74%)
     
  • FTSE 100

    7,202.95
    -31.08 (-0.43%)
     
  • Nikkei 225

    29,025.46
    +474.56 (+1.66%)
     

FDA Approves First And Only Twice-Yearly Schizophrenia Drug

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has approved a long-acting schizophrenia drug from Janssen, a unit of Johnson & Johnson (NYSE: JNJ)

  • Previously known as paliperidone palmitate, Invega Hafyera is a twice-yearly injectable. It's the first and only twice-yearly med for the condition.

  • The new long-acting regime joins J&J's existing one-month and three-month formulations, dubbed Invega Sustenna and Invega Trinza, respectively, plus a two-week injection known as Risperdal Consta.

  • The FDA based its approval on the results from a 702-patient Phase 3 trial. In that study, investigators found that the six-month formulation's performance held up with those already using the three-month injection to avoid relapse.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: JNJ shares are up 0.10% at $173.30 during the market session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.